This small but promising biotech recently had its U.S. debut and analysts say it could deliver a triple-digit return over the next twelve months.
Read MoreAnalysts see double-digit upside ahead for 2 of these 10 stocks.
Read MoreShares of 3M Co. (MMM) endured double-digit losses during the Thursday session after the multinational manufacturing giant missed big on Q1 earnings estimates. Earlier in the session, the stock was on track to be the biggest loser on the S&P 500 as well as on track to suffer its largest single-day loss in more than […]
Read MoreWe could see the S&P at 3,000 this year, according to JPMorgan’s strategists. Here’s why.
Read MoreAnybody that follows the market with any kind of regularity knows who Jim Cramer is. After establishing a solid reputation as a money manager running his own hedge fund in the 1990’s, where he gained fame by posting only a single year of negative returns, Cramer retired from money management in 2001 and began running […]
Read MoreGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a […]
Read More